Schizophrenia News and Research

Latest Schizophrenia News and Research

Scientists find seven new genes that can cause X-linked intellectual disability

X-linked intellectual disability is a disorder that predominantly affects men and can have highly variable clinical manifestations. Scientists at the Max Planck Institute for Molecular Genetics in Berlin have found seven new genes that can cause this genetic disease: Mutations of these genes on the X chromosome lead to various forms of intellectual disability.

15 Feb 2015

UM one step closer to developing potential drug for treating brain cancer

Promentis Pharmaceuticals, Inc. recently announced it will enter an exclusive agreement with UM to commercialize a discovery made by a team of UM faculty scientists that has the potential to treat brain cancer and possibly other disorders of the central nervous system.

11 Feb 2015

Added benefit of lurasidone drug not proven for schizophrenia

The drug lurasidone (trade name Latuda) has been available since November 2014 for the treatment of adults with schizophrenia. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

8 Feb 2015

Psychiatric Times introduces new information on anxiety disorders

UBM Medica US announces that Psychiatric Times, a leading online community for mental health professionals, introduces the latest information on anxiety disorders.

6 Feb 2015

Researchers report that neurons in the brain are connected like a social network

Neurons in the brain are wired like a social network, report researchers from Biozentrum, University of Basel. Each nerve cell has links with many others, but the strongest bonds form between the few cells most similar to each other.

5 Feb 2015

Endogenous cannabinoids linked to weight gain in people with schizophrenia

Cannabinoids may be involved in the weight gain that occurs in people with schizophrenia who are treated with the antipsychotic olanzapine, according to a pilot study published in the Journal of Clinical Psychopharmacology by researchers at the Institut universitaire en santé mentale de Montréal and Université de Montréal.

5 Feb 2015

Johns Hopkins student wins NCRC's 2015 Grand Prize

The National Collegiate Research Conference sponsored by the Harvard College Undergraduate Research Association awarded its 2015 Grand Prize to Mahima Sukumar, an undergraduate student at The Johns Hopkins University, working in the lab of Keri Martinowich, Ph.D., at the Lieber Institute for Brain Development.

5 Feb 2015

Researchers identify a common pattern across different psychiatric disorders

In a study analyzing whole-brain images from nearly 16,000 people, researchers at the Stanford University School of Medicine identified a common pattern across a spectrum of psychiatric disorders that are widely perceived to be quite distinct.

4 Feb 2015

EyeBrain raises €1.3 million ($1.47 million) through crowdfunding

EyeBrain, a company that develops markers of cerebral function for neurological and psychiatric disorders and diseases, today announces the conclusion of a new round of funding. A total of €1.3 million ($1.47 million) has been raised with the support of EyeBrain’s shareholders, the Fonds Régional de Co-Investissement d’Ile-de-France (FRCI, regional joint investment fund for the Ile-de-France or Greater Paris area) and the Anaxago crowdfunding platform.

4 Feb 2015

Scientists find eight different types of schizophrenia

Scientists from the universities of Granada (Spain) and Washington in St Louis (US) have found that there is not a single type of schizophrenia, but that it consists of a group made up of eight genetically different types of diseases, each of which presents its own set of symptoms.

4 Feb 2015

Study may offer insight into pathology of autism, Alzheimer's disease

For parents of children struggling with autism, the dearth of information is heartbreaking. Medical professionals are hard put to answer the primary questions: Who is autistic? What causes autism? What treatments are available? The situation is similar for Alzheimer's patients and relatives, who are helpless before the aggressive disease devouring a sufferer's identity.

4 Feb 2015

New research on dopamine-containing neurons could pave way for treating neurological disorders

Scientists studying hatchling fish have made a new advance in studying a chemical in the brain that impacts on movement.

2 Feb 2015

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.

31 Jan 2015

Study helps develop better understanding of how dopamine influences behaviour

Scientists studying hatchling fish have made a new advance in studying a chemical in the brain that impacts on movement.

29 Jan 2015

People who carry longevity gene variant have larger brain region

People who carry a variant of a gene that is associated with longevity also have larger volumes in a front part of the brain involved in planning and decision-making, according to researchers at UC San Francisco.

29 Jan 2015

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

The Alzheimer's Drug Discovery Foundation announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI).

28 Jan 2015

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.

23 Jan 2015

International study identifies genetic factors that influence the size of brain structures

An international study, which included researchers from NUI Galway, has identified significant genetic factors that influence the size of structures within the brain. It is hoped these new insights may help scientists better understand disorders such as schizophrenia, Alzheimer's disease and epilepsy.

23 Jan 2015

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, announces significant progress in its drug discovery collaboration with AstraZeneca.

22 Jan 2015

Hallucinations linked to self-destructive thoughts among adolescents with psychological symptoms

Visual distortions and hallucinations related to an elevated risk of psychosis are linked to self-destructive thought processes among adolescents with psychological symptoms, according to a recent Finnish study. Early indications of the risk of psychosis can usually be detected long before the onset of a full-blown disorder.

22 Jan 2015

Schizophrenia News and Research

Latest Schizophrenia News and Research

Scientists find seven new genes that can cause X-linked intellectual disability

UM one step closer to developing potential drug for treating brain cancer

Added benefit of lurasidone drug not proven for schizophrenia

Psychiatric Times introduces new information on anxiety disorders

Researchers report that neurons in the brain are connected like a social network

Endogenous cannabinoids linked to weight gain in people with schizophrenia

Johns Hopkins student wins NCRC's 2015 Grand Prize

Researchers identify a common pattern across different psychiatric disorders

EyeBrain raises €1.3 million ($1.47 million) through crowdfunding

Scientists find eight different types of schizophrenia

Study may offer insight into pathology of autism, Alzheimer's disease

New research on dopamine-containing neurons could pave way for treating neurological disorders

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

Study helps develop better understanding of how dopamine influences behaviour

People who carry longevity gene variant have larger brain region

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

International study identifies genetic factors that influence the size of brain structures

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Hallucinations linked to self-destructive thoughts among adolescents with psychological symptoms

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Schizophrenia News and Research

Latest Schizophrenia News and Research

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in